Year 2021 / Volume 28 / Number 5

Abstract PDF HTML

Cilinical Note

Late onset of restless legs syndrome as a methadone withdrawal symptom in cancer patients: report of two cases

Rev. Soc. Esp. Dolor. 2021; 28(5): 298-300 / DOI: 10.20986/resed.2021.3889/2021

María Alejandra Herrera, Nora Marcela Mendoza, Alberto Fernández


ABSTRACT

Restless legs syndrome is a frequent sleep disturbance, which usually involves an urgent desire to move the legs, associated with an unpleasant sensation and periodic movements of the legs during sleep. Its pathophysiology has been widely studied and is still not completely clear, and it is currently understood that it is influenced by personality, genetic and environmental factors. In this paper we describe 2 cases in which the suspension of methadone treatment was considered strongly associated with the presentation of restless legs syndrome in patients without previous diagnosis of this syndrome.



RESUMEN

El síndrome de piernas inquietas es una alteración del sueño frecuente, el cual involucra usualmente un deseo urgente de mover las piernas, asociado con una sensación displacentera y movimientos periódicos de las mismas durante el sueño. La fisiopatología de este síndrome ha sido ampliamente estudiada y aun no es completamente clara, entendiéndose en la actualidad que en el mismo influyen factores de la personalidad, genéticos y ambientales. En el presente escrito describimos 2 casos en los cuales la suspensión del tratamiento con metadona se consideró fuertemente asociada a la presentación de síndrome de piernas inquietas en pacientes sin diagnóstico previo del mismo.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev. 2012;5 (5):CD007834. doi: 10.1002/14651858.CD007834.pub2.
DOI: 10.1002/14651858.CD007834.pub2
2. Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283-95. DOI: 10.1016/j.smrv.2011.05.002.
DOI: 10.1016/j.smrv.2011.05.002
3. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res. 2002;53(1):547-54. DOI: 10.1016/s0022-3999(02)00443-9.
DOI: 10.1016/S0022-3999(02)00443-9
4. Ekbom KA. Restless legs syndrome. Neurology. 1960;10:868-73. DOI: 10.1212/wnl.10.9.868.
DOI: 10.1212/WNL.10.9.868
5. Çurgunlu A, Döventaş A, Karadeniz D, Erdinçler DS, Oztürk AK, Karter Y, et al. Prevalence and characteristics of restless legs syndrome (RLS) in the elderly and the relation of serum ferritin levels with disease severity: hospital-based study from Istanbul, Turkey. Arch Gerontol Geriatr. 2012;55(1):73-6. DOI: 10.1016/j.archger.2011.06.002.
DOI: 10.1016/j.archger.2011.06.002
6. Srivanitchapoom P, Pandey S, Hallett M. Restless legs syndrome and pregnancy: a review. Parkinsonism Relat Disord. 2014;20(7):716-22. DOI: 10.1016/j.parkreldis.2014.03.027.
DOI: 10.1016/j.parkreldis.2014.03.027
7. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol. 2005;4(8):465-75. DOI: 10.1016/S1474-4422(05)70139-3.
DOI: 10.1016/S1474-4422(05)70139-3
8. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12(5):440-4. DOI: 10.1016/j.sleep.2010.11.002.
DOI: 10.1016/j.sleep.2010.11.002
9. Patatanian E, Claborn MK. Drug-induced restless legs syndrome. Ann Pharmacother. 2018;52(7):662-72. DOI: 10.1177/1060028018760296.
DOI: 10.1177/1060028018760296
10. Anguelova GV, Vlak MHM, Kurvers AGY, Rijsman RM. Pharmacologic and nonpharmacologic treatment of restless legs syndrome. Sleep Med Clin. 2018;13(2):219-30. DOI: 10.1016/j.jsmc.2018.02.005.
DOI: 10.1016/j.jsmc.2018.02.005
11. Trenkwalder C, Zieglgänsberger W, Ahmedzai SH, Högl B. Pain, opioids, and sleep: implications for restless legs syndrome treatment. Sleep Med. 2017;31:78-85. DOI: 10.1016/j.sleep.2016.09.017.
DOI: 10.1016/j.sleep.2016.09.017
12. De Biase S, Merlino G, Valente M, Gigli GL. Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12(9):1035-45. DOI: 10.1080/17425255.2016.1198320.
DOI: 10.1080/17425255.2016.1198320
13. Salminen AV, Winkelmann J. Restless legs syndrome and other movement disorders of sleep-treatment update. Curr Treat Options Neurol. 2018;20(12):55. DOI: 10.1007/s11940-018-0540-3.
DOI: 10.1007/s11940-018-0540-3
14. Park YM, Cho JH, Lim YS, Lee HJ, Kang SG, Kim L. The withdrawal from TDF therapy could induce transient RLS. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):419-20. DOI: 10.1016/j.pnpbp.2009.12.006.
DOI: 10.1016/j.pnpbp.2009.12.006
15. Mackie SE, McHugh RK, McDermott K, Griffin ML, Winkelman JW, Weiss RD. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat. 2017;73:35-9. DOI: 10.1016/j.jsat.2016.10.001.
DOI: 10.1016/j.jsat.2016.10.001

Artículos relacionados

Care needs of intrathecal infusion therapy in patients with cancer pain

Rev. Soc. Esp. Dolor. 2023; 30(4): 227-242 / DOI: 10.20986/resed.2024.4099/2023

Pharmacogenetics in analgesic response: towards a sex-differences personalized medicine

Rev. Soc. Esp. Dolor. 2023; 30(2): 115-124 / DOI: 10.20986/resed.2023.4042/2022

Observational, prospective and multicenter study on the use of transmucosal fentanyl citrate in regular clinical practice for the control of breakthrough pain crises in cancer patients

Rev. Soc. Esp. Dolor. 2023; 30(2): 72-78 / DOI: 10.20986/resed.2023.4028/2022

Effects of transcranial direct current stimulation in pain and opioid consumption after spine surgery

Rev. Soc. Esp. Dolor. 2023; 30(1): 49-59 / DOI: 10.1002/ejp.1985

Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?

Rev. Soc. Esp. Dolor. 2023; 30(1): 7-14 / DOI: 10.20986/resed.2023.4010/2022

How to prevent the abuse of opioids without hindering access to them for those patients who need them?

Rev. Soc. Esp. Dolor. 2023; 30(1): 1-2 / DOI: 10.20986/resed.2023.4078/2023

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

OFA in major surgery. Experience at a secondary level hospital

Rev. Soc. Esp. Dolor. 2022; 29(1): 8-14 / DOI: 10.20986/resed.2022.3991/2022

Recommendations for the safe prescription of opioids in patients with a history or risk of abuse

Rev. Soc. Esp. Dolor. 2021; 28(6): 343-349 / DOI: 10.20986/resed.2022.3935/2021

New opioids with different intracellular mechanism of action; is a new therapeutic window opening up?

Rev. Soc. Esp. Dolor. 2021; 28(5): 292-297 / DOI: 10.20986/resed.2021.3891/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

The unsolved problem of postoperative pain: critical analysis and prospects for improvement

Rev. Soc. Esp. Dolor. 2021; 28(4): 232-238 / DOI: 10.20986/resed.2021.3917/2021

Psychological factors associated with the adherence to analgesic treatment in patients with chronic pain: systematic review of the literature

Rev. Soc. Esp. Dolor. 2021; 28(4): 181-193 / DOI: 10.20986/resed.2021.3922/2021

Postoperative ketamine efficacy in patients receiving chronic opioids undergoing spinal surgery

Rev. Soc. Esp. Dolor. 2021; 28(2): 92-99 / DOI: 10.20986/resed.2021.3825/2020

Risk of misuse of prescribed opioids in patients with chronic noncancer pain in a workers compensation system hospital in Chile

Rev. Soc. Esp. Dolor. 2021; 28(2): 82-91 / DOI: 10.20986/resed.2021.3845/2020

Evolution of low back pain in cancer patients treated with interventional pain management

Rev. Soc. Esp. Dolor. 2021; 28(2): 76-81 / DOI: 10.20986/resed.2021.3901/2021

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Parsonage-turner after rabies vaccination due to bat bite: case report

Rev. Soc. Esp. Dolor. 2021; 28(1): 57-61 / DOI: 10.20986/resed.2021.3832/2020

Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

Rev. Soc. Esp. Dolor. 2021; 28(1): 19-26 / DOI: 10.20986/resed.2021.3824/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

School of non-oncologic chronic pain patients and opioid treatment

Rev. Soc. Esp. Dolor. 2020; 27(5): 324-328 / DOI: 10.20986/resed.2020.3804/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Pain: a "hotchpotch"

Rev. Soc. Esp. Dolor. 2020; 27(4): 278-280 / DOI: 10.20986/resed.2016.3507/2016

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

Intraoperative methadone; an island among opioid free anesthesia drugs?

Rev. Soc. Esp. Dolor. 2020; 27(2): 140-142 / DOI: 10.20986/resed.2020.3789/2019

Management of breakthrough pain associated with the cure of skin ulcers

Rev. Soc. Esp. Dolor. 2020; 27(2): 113-126 / DOI: 10.20986/resed.2020.3755/2019

Efficacy of a preincisional analgesic strategy with ibuprofen, paracetamol and dexamethasone in laparoscopic cholecystectomy. Prospective observational study

Rev. Soc. Esp. Dolor. 2020; 27(2): 104-112 / DOI: 10.20986/resed.2020.3778/2019

Opioid formulations that prevent the recreational use: more questions than answers about their utility

Rev. Soc. Esp. Dolor. 2020; 27(1): 61-62 / DOI: 10.20986/resed.2018.3645/2017

Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review

Rev. Soc. Esp. Dolor. 2020; 27(1): 37-49 / DOI: 10.20986/resed.2020.3717/2018

Effectiveness of patient-controlled analgesia in acute and chronic pain after cardiac surgery: a prospective study

Rev. Soc. Esp. Dolor. 2020; 27(1): 24-36 / DOI: 10.20986/resed.2020.3747/2019

Opioid-induced constipation: the other epidemic

Rev. Soc. Esp. Dolor. 2020; 27(1): 1-2 / DOI: 10.20986/resed.2020.3794/2020

Key factors governing spinal cord opioid bioavailability in the management of acute pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 359-367 / DOI: 10.20986/resed.2019.3737/2019

Opioid tapering may improve outcomes for chronic pain patients

Rev. Soc. Esp. Dolor. 2019; 26(3): 204-205 / DOI: 10.20986/resed.2017.3615/2017

Dexmedetomidine as peripheral nerve block adjuvant

Rev. Soc. Esp. Dolor. 2019; 26(2): 103-115 / DOI: 10.20986/resed.2018.3695/2018

Fast opioid detoxification

Rev. Soc. Esp. Dolor. 2019; 26(2): 95-102 / DOI: 10.20986/resed.2019.3681/2018

Opioids and addiction in chronic pain: is it a problem?, how to address it?

Rev. Soc. Esp. Dolor. 2019; 26(2): 65-67 / DOI: 10.20986/resed.2019.3736/2019

Do our patients need opioids and benzodiazepines concurrently?

Rev. Soc. Esp. Dolor. 2019; 26(1): 59-60 / DOI: 10.20986/resed.2017.3552/2016

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

The use of opioids in older adults

Rev. Soc. Esp. Dolor. 2019; 26(1): 4-5 / DOI: 10.20986/resed.2019.3731/2019

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Farmacologic adyuvants with saving effect of opioids in the perioperative period

Rev. Soc. Esp. Dolor. 2018; 25(5): 278-290 / DOI: 10.20986/resed.2018.3663/2018

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Expenditure, prescription and consumption of analgesic drugs before and during the economic crisis

Rev Soc Esp Dolor 2018; 25(3): 155-162 / DOI: 10.20986/resed.2017.3609/2017

Pharmacological management of acute postoperative pain in Spain. Data from the national survey by the Spanish Pain Society (SED)

Rev Soc Esp Dolor 2018; 25(2): 70-85 / DOI: 10.20986/resed.2017.3593/2017

Control of symptoms in terminally ill patients: effectiveness of opioid treatment for breakthrough dyspnea

Rev Soc Esp Dolor 2017; 24(4): 161-168 / DOI: 10.20986/resed.2017.3582/2017

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Prescribing strong opioids in patients with non-cancer pain: a description of their characteristics in an area of primary healthcare assistance

Rev Soc Esp Dolor 2017; 24(1): 19-26 / DOI: 10.20986/resed.2016.3471/2016

Instrucciones para citar

Herrera M, Mendoza N, Fernández A. Late onset of restless legs syndrome as a methadone withdrawal symptom in cancer patients: report of two cases. Rev Soc Esp Dolor 2021; 28(5): 298-300 / DOI: 1020986/resed20213889/2021


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 11803 veces.
Este artículo ha sido descargado 3 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 17/01/2021

Aceptado: 20/11/2021

Prepublicado: 02/12/2021

Publicado: 04/01/2022

Tiempo de revisión del artículo: 279 días

Tiempo de prepublicación: 319 días

Tiempo de edición del artículo: 352 días


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad